Poly (d, l-lactide-co-glycolide)-phospholipid nanocarrier for efficient delivery of macular pigment lutein: absorption pharmacokinetics in mice and antiproliferative effect in Hep G2 cells
- 118 Downloads
Lutein has various biological activities, its application in food and pharma industries are limited due to poor aqueous solubility, stability, and bioavailability. To achieve various benefits, lutein-poly (lactic-co-glycolic acid) (PLGA)-phospholipid (PL) nanocapsules were prepared. Lutein-PLGA NCs (+PL) were synthesized, characterized and its bioavailability was studied in vitro and in vivo. The cellular uptake and anti-proliferative activity were analyzed in Hep G2 cells. The mean size and zeta value of lutein-PLGA NCs (+PL) were 140 ± 6 nm and − 44 mV. The amorphous nature of lutein in PLGA NCs (+PL) was confirmed by XRD and DSC. In vitro lutein release kinetics showed an initial burst followed by sustainable release up to 86%. In vitro bioavailability showed 62.7% higher lutein bioaccessibility than lutein in free form. The AUC of lutein after single oral dose of lutein-PLGA NCs (+PL) revealed 3.91-fold (plasma), 2.89-fold (liver), and 3.12-fold (eyes) higher absorption than the control (mixed micelles). The IC50 of lutein-PLGA NCs (+PL) in Hep G2 cells at 72 h was 4.5 μM as opposed to 23.4 μM for lutein in free form. Thus, results reveal that PL added to PLGA NCs helps in enhancing the solubility which in turn resulted in its better bioavailability and bioefficacy.
KeywordsBiomaterials Bioavailability Carotenoids Hep G2 Lutein Nanocapsules PLGA Phospholipids Stability
R. Arunkumar acknowledges Indian Council of Medical Research (ICMR), Govt. of India for awarding Senior Research Fellowship.
This research project was financially supported by the Department of Science and Technology (DST), Govt. of India (DST, INT/JSPS/P-122/11)
Compliance with ethical standards
Manuscripts submitted for publication must contain a declaration that the experiments comply with the current laws of the country in which they were performed.
All institutional and national guidelines for the care and use of laboratory animals were followed.
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Chew BP, Wong MW, Wong TS. Effects of lutein from marigold extract on immunity and growth of mammary tumors in mice. Anticancer Res. 1996;16:3689–94.Google Scholar
- 14.Arunkumar R, Prashanth KVH, Manabe Y, Hirata T, Sugawara T, Dharmesh SM, et al. Biodegradable poly (lactic-co-glycolic acid)–polyethylene glycol nanocapsules: an efficient carrier for improved solubility, bioavailability, and anticancer property of lutein. J Pharm Sci. 2015;104:2085–93.CrossRefGoogle Scholar
- 20.Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. 2009;29:3867–75.Google Scholar
- 28.Shanmugam S, Baskaran R, Balakrishnan P, Thapa P, Yong CS, Yoo BK. Solid self-nanoemulsifying drug delivery system (S-SNEDDS) containing phosphatidylcholine for enhanced bioavailability of highly lipophilic bioactive carotenoid lutein. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Für Pharm Verfahrenstechnik EV. 2011;79:250–7.Google Scholar
- 31.Deming DM, Erdman JW. Mammalian carotenoid absorption and metabolism. Pure Appl Chem [Internet]. 1999 [cited 2016 Jan 21];71. Available from: http://www.degruyter.com/view/j/pac.1999.71.issue-12/pac199971122213/pac199971122213.xml